A strong intellectual property strategy lies at the heart of how we serve our CDMO clients. Our technologies provide a broad range of release profiles, taking into account the physical and chemical characteristics of a drug, the therapeutic use, and the optimal site for release of the active pharmaceutical ingredient in the body.

Control Release Delivery Platforms

Hypermatrix™

Proprietary, multidimensional controlled-release platform designed to optimize drug delivery profiles.

Allows precise modulation of drug release rates in response to the gastrointestinal tract's environment.

Hypermatrix™ enhances therapeutic efficacy and patient compliance.

Applicable to both new and existing pharmaceuticals, Hypermatrix™ supports the development of products across various therapeutic classes.

know More

nPODDDS™

Designed to modulate drug release profiles through a strategic divergence point.

Initiates with a rapid release phase to achieve therapeutic levels, followed by a sustained release phase that maintains consistent drug.

nPODDDS™ resists common tampering methods, such as crushing or dissolving, and mitigates the risk of dose dumping, particularly in the presence of alcohol.

Initially applied to opioid analgesics, the nPODDDS™ platform is adaptable to a broad range of time-release medications.

Know More

Other CR Platforms

Using our Hypermatrix™ concept, we have designed several controlled-release delivery platforms: IntelliFoam™, IntelliGITransporter™, IntelliMatrix™, IntelliOsmotics™, IntelliPaste™, IntelliShuttle™ and IntelliPellets™.

Know More

Abuse Deterrent Technology

Medicap Labs’ ADT platform is designed to prevent misuse of controlled drugs while preserving their therapeutic performance. Our formulations resist tampering methods such as crushing, chewing, dissolving, or injecting, using robust physical and chemical barriers. These technologies maintain precise drug release profiles, ensuring efficacy and safety for patients. ADT also meets evolving regulatory standards, supporting responsible prescribing and minimizing the risk of abuse.

Know More →

Overdose Prevention Technology

PODRAS™

A platform engineered to mitigate the risk of overdose and abuse by modulating drug release based on dosage intake.

Release less active pharmaceutical ingredient when more tablets than prescribed are ingested, PODRAS™ ensures that therapeutic efficacy is maintained at prescribed doses while reducing the potential for misuse.

Incorporates multiple safeguards, including resistance to common tampering methods.

The FDA granted Fast Track designation to an oxycodone hydrochloride ER product candidate utilizing PODRAS™, acknowledging its potential to address unmet medical needs in abuse deterrence.

Know More →